Resources Repository
-
ArticlePublication 2015A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening
General frameworks of the cancer screening process are available, but none directly compare the process …
General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. This paper presents a conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based…
Evidence Synthesis | Test Performance | Health Outcomes | Science/Technology | Health Systems | Preferences/Values | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Decision Analysis | Government/Law | Science/Technology | Health Systems | Dynamic Transmission | Risk Analysis | Infectious Diseases | Policy/Regulation | Health/Medicine | Global -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Costing Methods | Government/Law | Science/Technology | Health Systems | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2015Cancer Models and Real-World Data: Better Together
Decision-analytic models synthesize available data on disease burden and intervention effectiveness to project estimates of …
Decision-analytic models synthesize available data on disease burden and intervention effectiveness to project estimates of the long-term consequences of care. While models have been influential in informing US cancer screening guidelines under ideal conditions, incorporating detailed data on real-world screening practice has been limited given the complexity of screening processes and behaviors throughout diverse health delivery systems in the United States. The authors describe the synergies that exist between decision-analytic models and health care utilization…
Evidence Synthesis | Calibration/Validation | Science/Technology | Health Systems | Mathematical Models | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Costing Methods | Health Outcomes | Science/Technology | Health Systems | Cost-Effectiveness Analysis | Global Governance | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2014Economic Implications of Population Ageing in China & India: Introduction to the Special Issue
In this special issue of The Journal of the Economics of Ageing, we focus on economic …
In this special issue of The Journal of the Economics of Ageing, we focus on economic aspects of population ageing in the world’s two population superpowers: China and India. China and India have been the subject of comparison for many years. Observations about their relative political and economic development abound (see for example Sen, 2013), but little analysis is currently available of their comparative demographic trajectories and the possible economic consequences of the population ageing that they are both undergoing. These demographic…
Costing Methods | Health Outcomes | Government/Law | Health Systems | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Health/Medicine | Asia & Pacific -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Costing Methods | Health Outcomes | Science/Technology | Health Systems | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2020Infectious Disease Pandemic Planning and Response: Incorporating Decision Analysis
During a pandemic, decisions must be made under rapidly changing, uncertain conditions. Despite advances in …
During a pandemic, decisions must be made under rapidly changing, uncertain conditions. Despite advances in analytical methods for gaining early situational awareness (i.e., of a disease’s transmissibility and severity) and for predicting the likely effectiveness of interventions, a major gap exists globally in terms of integrating this information in policy documents. The authors argue that mathematical and statistical models are important tools for pandemic planning and response. Once an outbreak of pandemic potential has been…
Decision Analysis | Government/Law | Health Systems | Mathematical Models | Health/Medicine | Global -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Government/Law | Health Systems | Probability/Bayes | Technology Assessment | Infectious Diseases | Policy/Regulation | Health/Medicine | Global | North America